Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : ViiV Healthcare and the Medicines Patent Pool expand access to dolutegravir-based regimens for people living with HIV in Azerbaijan, Belarus, Kazakhstan and Malaysia

12/01/2020 | 08:58am EST

London - ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc ('GSK'), with Pfizer Inc. and Shionogi Limited as shareholders, and the Medicines Patent Pool (MPP) today announced the signing of a new voluntary licensing agreement to enable greater access in certain upper-middle-income countries (UMICs) to dolutegravir (DTG)-based regimens which have been recommended by the World Health Organization (WHO)1 or the US Department of Health and Human Services2 (DHHS).

These countries are Azerbaijan, Belarus, Kazakhstan and Malaysia.

Recognising the specific challenges faced by these countries and in response to feedback from the HIV community and the governments, ViiV Healthcare and MPP have created this first-of-its-kind agreement to enable increased access and affordability to generic DTG-based HIV treatment regimens, while also supporting continued investment in much needed innovation. Through this novel agreement, selected generic manufacturers will have the opportunity to supply DTG-based medicines at a significantly reduced price compared to local prices at the time of this agreement, in turn enabling greater access to these medicines for people living with HIV in each country.

Charles Gore, MPP Executive Director said, 'Increasing access to life-saving medicines for low- and middle-income countries is at the core of our mission and we have been able to achieve that over the last 10 years through strong partnerships that span industry, generics manufacturers, governments and civil society. This new and first-of-its-kind agreement with ViiV Healthcare, that is specifically aimed at increasing access in these upper middle-income countries, will mean that people living with HIV in Azerbaijan, Belarus, Kazakhstan and Malaysia will have greater access to affordable WHO-recommended DTG-based treatment regimens.'

Dr Meg Doherty, Director of Global HIV, Hepatitis and STI Programmes at WHO said: 'WHO recommends the use of DTG as part of the preferred first-line and second-line regimen for people living with HIV, including pregnant women and those of childbearing potential. WHO welcomes this licence and through our regional and country offices have worked alongside governments and MPP to ensure that this agreement responds to people's HIV treatment needs in these countries.'

ViiV Healthcare and MPP will now work closely with governments and selected generic manufacturers to make generic DTG-based regimens available as soon as possible in the four countries.

Deborah Waterhouse, CEO at ViiV Healthcare said, 'We are 100% committed to our mission of leaving no person living with HIV behind and are proud to have built upon our existing partnership with MPP to enable improved access to DTG in these upper-middle-income countries, in line with WHO HIV treatment guidelines. Through this agreement, we have created a new model that enables improved access to treatment and increased affordability while supporting continued investment in research and development of much needed innovative medicines to help ensure better long-term outcomes for people living with HIV.'

About the Medicines Patent Pool

MPP is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP's main funder. MPP's work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company's aims are to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Contact:

Gelise McCullough

Tel: +41 79 685 64 36

Email: gmccullough@medicinespatentpool.org

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk Factors' in the company's Annual Report on Form 20-F for 2019 and as set out in GSK's 'Principal risks and uncertainties' section of the Q3 Results and any impacts of the COVID-19 pandemic.

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 1.13% 1380.2 Delayed Quote.2.85%
PFIZER INC. 0.19% 36.55 Delayed Quote.-0.71%
All news about GLAXOSMITHKLINE PLC
01/22GlaxoSmithKline-Owned ViiV Healthcare Says US FDA Approved its HIV Drug Caben..
MT
01/22GLAXOSMITHKLINE : ViiV Healthcare announces FDA approval of Cabenuva (cabotegrav..
AQ
01/22MARKET CHATTER : Pfizer, BioNTech Reportedly Agree to Supply Vaccine for WHO-Bac..
MT
01/22BIONDVAX PHARMACEUTICALS : Announces Appointment of Amir Reichman as New CEO
AQ
01/22GLAXOSMITHKLINE : GSK - ViiV Healthcare announces FDA approval of Cabenuva, the ..
AQ
01/22IMMUTEP : Says Partner Glaxo Has Discontinued Phase II Study of Ulcerative Colit..
MT
01/21GSK Unit ViiV Healthcare's HIV-1 Infection Gets US FDA Approval
MT
01/21GlaxoSmithKline Subsidiary ViiV Healthcare's Regimen for HIV-1 Gets FDA Appro..
MT
01/21GLAXOSMITHKLINE : Viiv Healthcare Announces FDA Approval Of Cabenuva For HIV Tre..
RE
01/21Pfizer-BioNTech agree to supply WHO co-led COVID-19 vaccine scheme -sources
RE
More news
Financials
Sales 2020 34 212 M 46 818 M 46 818 M
Net income 2020 4 888 M 6 690 M 6 690 M
Net Debt 2020 22 612 M 30 944 M 30 944 M
P/E ratio 2020 14,0x
Yield 2020 5,80%
Capitalization 68 876 M 94 107 M 94 255 M
EV / Sales 2020 2,67x
EV / Sales 2021 2,58x
Nbr of Employees 99 437
Free-Float 92,3%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 1 684,69 GBX
Last Close Price 1 380,20 GBX
Spread / Highest target 70,3%
Spread / Average Target 22,1%
Spread / Lowest Target -19,9%
EPS Revisions
Managers and Directors
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC2.85%94 107
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159